Assessment of The Immunization Status of Individuals Vaccinated By Hepatitis B Virus Vaccine In Khartoum State

Authors

  • Kafi SK Department of microbiology, Faculty of Medical laboratory Science, The National Ribat University, Khartoum, Sudan
  • Khalil SSO University of Medical Sciences and Technology, Khartoum, Sudan
  • Musa HA Department of microbiology, Faculty of Medicine, The National Ribat University, Khartoum, Sudan.

DOI:

https://doi.org/10.52981/sjms.v8i3.903

Keywords:

Hepatitis B vaccine, Immunization, IgG, IgM

Abstract

Background: Hepatitis B virus (HBV) is widely distributed all over the world. Quite a large number of the population worldwide is exposed to the virus. It is estimated that 378 million are chronically infected and at risk of developing serious complications like liver cirrhosis and hepatocelluar carcinoma leading to death. Fortunately, an effective vaccine has been introduced to prevent infection with the virus. The rate of infection by HBV has been effectively reduced by universal vaccination with that vaccine. Post-vaccination concentration of vaccine induced neutralizing antibodies against HBsAg above 10 mlU is considered protective against the virus.
Objectives: To assess the state of immunization of Sudanese individuals previously vaccinated by HBV vaccine in Khartoum State.
Methodology: A total of 90 individuals previously vaccinated with HBV vaccine and 70 unvaccinated persons (control) had their blood tested anti-HBsAg. Specimens negative for anti-HBs Ag were further tested for total (IgM & IgG) anti-HBcAg and HBsAg by ELISA. Specimens positive for total anti- HBcAg were further tested for IgM anti-HBcAg.
Results: The majority 76(88.4%) of the vaccinated subjects and 4.28% of the control were found to be positive for anti-HBsAg. Out of the 76 subjects with positive antibody response; 68.4% showed good antibody response (protected against the virus). The remaining (31.6%) showed low antibody response and are therefore at risk of infection. In general 42.2% of the vaccinated subjects and all the control group revealed low or no antibody response and are at risk of infection. The results of this study showed statistically significant difference in the antibody response between those who received three vaccine doses (72.7%) and one dose (18.8%) with P value < 0.05. Two (2.22%) of the vaccinated subjects have developed HBV infection, compared to four (5.71%) of the control group.
Conclusion: Antibody response to HBV vaccine was found 88.4% of the vaccinated subjects, however, considerable number of the vaccinated subjects revealed low or no antibody response. Individuals, who received three doses of the vaccine, had statistically significant antibody response than those who received only one dose.

References

1. Hollinger FB and Liang TJ. Hepatitis B Virus. In: Knipe DM et al., eds Fields Virology, 4th ed. Philadelphia, Lippincott Williams & Wilkins, 2001; 2971 - 3036.
2. Robinson WS. Hepatitis B viruses. General features (human). In: Webster RG and Granoff A, eds. Encyclopedia of virology, London, Academic press Ltd, 1994; 554 - 569.
3. Mahoney FJ and Kane M (). Hepatitis B vaccine. In: Plotkin SA and Orenstein WA, eds. Vaccines, 3rd ed. Philadelphia, W.B. Saunders Company, 1999; 158 -182.
4. Gasim I. Gasim, Hamdan Z. Hamdan, Sumaia Z. Hamdan and Ishag Adam. Epidemiology of Hepatitis B and Hepatitis C virus infection among hemodialysis patients in Khartoum, Sudan. Journal of Medical Virology 2012; 84:52 - 55.
5. Howard CR and Allison LMC. Hepatitis B surface antigen variation and protective immunity. Intervirology 1995; 38:35 - 40.
6. Wolfagang Jilg, Emilia Sieger, Reinhart Zachoval, Hermann Schätz. Individuals with antibodies against hepatitis B core antigen as the only serological marker for hepatitis B virus infection: high percentage of carriers of hepatitis B and C virus. J Hepatol. 1995; 23 (1)14 -20.
7. WHO. Hepatitis B vaccines. Releve epidemiologique hebdomad aire/ Section d'hygiene du Secretariat de la Societe des Nations, Weekly Epidemiol Rec/ Health section of the Secretariat of the league of Nations 2009; 84: 405 - 419.
8. Jongerius JM, Wester M, Cuypers HT, van Oostendorp WR, Lelie PN, van der Poel CL, van Leeuwen EF.. New hepatitis B virus mutant form in a blood donor that is undetectable in several hepatitis B surface antigen screening assays. Transfusion 1998; 38: 56 – 59.
9. Odusanya OO, Alufohai E, Meurice FP, Ahonkhai VI. Five- years post vaccination efficacy of hepatitis B vaccine in rural Nigeria. Human Vaccin 2011; 7(6): 625 - 9.
10. Yen-Hsuan NI, Mei-Hwei Chang, Li-Min Huang, Huey-ling Chen, Hong-Yuan Hsu, Tai-Yuan Chiu, Keh- Sung Tsai and Ding-Shinn Chen. Hepatitis B virus infection in children and adolescents in Hyperendemic Area: 15 years after Mass Hepatitis B vaccination. Annals of internal medicine 2001;135 (9):796-800.
11. 11. Capagna M, Siddu A, Meloni A, Murru C, Masia G, Coppola RC. Epidemiological impact of Mandatory vaccination against hepatitis B in italian young Adults. Hepat Mon. 2011; 11(9): 750 - 2.
12. 12. Voranush Chongsrisawat, Pornsak Yoocharoen, Apiradee Theamboonlers, Piyanit Tharmaphornpilas, Porpit Warinsathien, Supakarn Sinlaparatsamee, Siriraj Paupunwatana, Kasemporn Chaiear, Sawan Khwanjaipanich and Yong Poovorawan. Hepatitis seroprevalence in Thailand: 12 years after hepatitis B vaccine integration into the national expanded programme on immunization. Trop Med Int Health 2006; 11(10):1496-502

Downloads

Published

2021-08-14

Issue

Section

Original Articles